Prognostic-disability Biomarkers in Multiple Sclerosis: Review of the Literature from the Last Five Years
Journal Title: UNKNOWN - Year 2018, Vol 24, Issue 3
Abstract
With the advent of new agents in the treatment of multiple sclerosis, new treatment modalities have emerged (escalation-induction therapy) and the increased efficacy of the drugs has led to increased drug-related risks. The risk/benefit balance has become more carefully assessed. The increased need for reliable markers to predict prognosis-disability has also led to an increase in research conducted in this area. In this short review, studies published between 2012-2017, especially those related to prognosis and disability, were compiled.
Authors and Affiliations
Nefati Kıylıoğlu
Keywords
Related Articles
- EP ID EP392434
- DOI 10.4274/tnd.79836
- Views 62
- Downloads 0
A Rare Cause of Myelopathy: Os Odontoideum
.
The Adverse Effects of High-dose Corticosteroids with Early and Late Severe Morbidity in the Treatment of Patients with Multiple Sclerosis: Long-term Observation Results
Objective: Intravenous methylprednisolone (IVMP) is the most commonly used emergency treatment for multiple sclerosis (MS) attacks and the risk of adverse effects is high due to frequent use. The aim of our study was to...
The Assesment of Efficacy of Traditional and Complementary Medicine Practices in Neurology
Traditional, complementary, and alternative medicine practices are used in the prevention, diagnosis, and treatment of a wide variety of diseases in the world. Such practices in Turkey are regulated by the “Regulation of...
Anti-N-methyl-D-aspartate receptor encephalitis in children: a case report
.
Brain Metastasis in a Patient with Malignant Melanoma: Melanotic Pattern
.